Current assignment concerns the conclusion of
- an agreement for the purchase (for UZ Leuven and UZ Gent) with maintenance of mass spectrometers (lot 1) and
- a 5-year agreement for the purchase of associated reagents for neonatal screening applied to the mass spectrometer (lot 2).

This assignment is part of the 5-yearly re-tender of the Flemish Government in this regard, for which UZ Gent and UZ Leuven have jointly applied.

The decision in the Flemish Government's tender will probably be made at the end of 2024 – beginning of 2025.

However, since the Flemish Government requires that the tenderer to whom the contract will be awarded employs a functional laboratory as soon as possible, the procedures for setting up the laboratory must already be started.

If Ghent University Hospital and Leuven are not awarded the assignment by the Flemish Government, this assignment will also become devoid of purpose and will therefore be discontinued.

LOT-0001
P8143
the conclusion of an agreement for the purchase of two triple quadrupole LC mass spectrometers (one for UZ Leuven and one for UZ Gent) suitable for UHPLC-MS measurements.
The purchase includes the delivery and commissioning with maintenance of these two triple quadrupole LC mass spectrometry systems suitable for UHPLC-MS measurements for neonatal screening.

UZ Leuven will proceed with the purchase of 1 of these devices. Ghent University Hospital will proceed with the purchase of the other device.

In both cases, the tenderer will also have to provide maintenance.

These systems include the mass spectrometers, the necessary columns and systems that enable column management, the necessary software, the link to the LIS and all other equipment and support to make neonatal screening technically possible on the devices.

LOT-0002
P8144
concluding a 5-year agreement for the purchase of neonatal screening kits applied to the mass spectrometer.
This lot includes everything needed from kits with control equipment to enable appropriate neonatal screening via mass spectrometry, both for UZ Leuven and UZ Gent.

The necessary kits should be suitable for analysis of amino acids and acylcarnitines for screening for the following conditions:
- Phenylketonuria (PKU) and hyperphenylalaninemia,
- Maple Syrup Urine Disease (MSUD),
- Tyrosinemia type I and type II (1st tier succinylacetone),
- Homocystinuria (1st tier methionine),
- Methylmalonic acidemia (MMA),
- Propionic acidemia (PA),
- Isovalerian acidemia (IVA),
- Glutaric acidemia type 1 (GA1)
- Carnitine Palmitoyltransferase Deficiency 1 (CPT1)
- Medium-chain acyl-CoA dehydrogenase deficiency (MCADD)
- Multiple acyl-CoA dehydrogenase deficiency (MADD)
- adenosine and deoxyadenosine for diagnosis of ADA/SCID

The probable quantities per year are based on the 63,000 births in 2022 plus 10%. The calculation of that 10% takes into account the number of recalls/retests and second and third injections in premature babies.